NFKB1 and myeloid sarcoma: Of note, because enhanced immune response may benefit MS patients by eliminating microbes, and because NDP52 negatively regulates TLR-triggered NF-κB activation, the NDP52G140E variant protective effect in MS was also tested on the activation of NF-κB, following TLR stimulation [18].